

Community Pharmacy Avon

Report and Accounts

2022-23

¹⁴a High Street, Bristol BS16 5HP

https://avon.communitypharmacy.org.uk



Chair's Annual Report

Once again it has been a very challenging year for community pharmacy. I know that every day pharmacy teams across Avon go above and beyond the call of duty to care for their patients. Considering the work force crisis and the drug shortages what community pharmacy has achieved has been outstanding and I am immensely proud.

I am delighted with the progress that we have made with service delivery. Many more pharmacies are engaged with services and the delivery of NMS, CPCS, PGDs and HCFS are all on the increase. Fully engaging with clinical services is imperative in taking our profession forward and gives us the vital evidence to demonstrate our value to government and the NHS. These services also give community pharmacists the opportunity to showcase their clinical skills to the public.

As Chair of Community Pharmacy Avon I am very proud once again of what we have achieved. I would like to thank all committee members for their hard work and support.

I am also extremely grateful for all the hard work and dedication shown by the Operations team. Richard Brown (Chief Officer), Judith Poulton (Implementation Manager), Roger Herbert (Pharmacy Support), Anne Cole (Independent Prescribing Lead) and Debbie Scudamore (Engagement Officer), who work tirelessly on behalf of the contractors.

The appetite is growing momentum for community pharmacists to become independent prescribers. This is the future of community pharmacy and will give us the clinical role that we so desire. I fully appreciate the challenges involved to achieve this and I assure you that Community Pharmacy Avon will support you every step of the way.

Lisa

Lisa Fisher MRPharmS

Chair





Chief Officer's Report

2023 marks the year when the NHS decided to commission, across England, a set of PGDs to allow pharmacists to issue prescription only medicines for common conditions (Pharmacy First). Do not underestimate the importance of this service in influencing the future direction of travel for our profession, do recognise the pivotal role all of you played in enabling this to happen. It is no coincidence that the excellent engagement delivered by Avon pharmacies in relation to our locally commissioned PGDs was noticed and recognised in the list of conditions being nationally commissioned. This outcome would not have been possible without the unwavering support of the LPC Operations Team. With Roger leading, supported by Judith linking in CPCS and Barbara (and now Lisa) facilitating surgery conversations, meant that the performance was a whole team effort.

This achievement sets the tone for the LPC. We are committed to supporting you, the pharmacy contractor, and this is evident in our recruitment of Anne who leads on our Independent Prescribing programme support. In our 2022 Annual Conference, you asked for more support in relation to IP and navigating the training requirements. We listened to you, and in October, we welcomed Anne to the team one day per week. This has meant we now have a more detailed understanding about who is currently a qualified IP, who is in training and who wants to undertake the course. This support has already more than doubled the interest in becoming an IP and will enable us to deliver the NHS IP Pathfinder Project when it launches later this year.

We also work closely with our ICBs (BNSSG and BSW), who from April 2023, hold our delegated pharmacy contract. This means we hold a seat on the key strategic and operational committees which will enable us to continue making a difference to pharmacy commissioning. This extremely positive relationship was evident with both ICBs present at our Annual Conference in July 2023. It's at this point that I want to also thank Debbie, the LPC Engagement Officer, for not only the excellent conference that she arranged, but also for the organisation she brings to the committee and operations team.

Lastly, during 2023 and beyond, the LPC will continue to work flat out in our representation to ensure you are sustainable in the years to come and please, always remember, the LPC is here to support you. If you need us, just ask.

Kind regards,

Richard

Richard Brown PhD FRPharmS Chief Officer





Treasurer's Report for 2022-2023

To All Contractors in Avon,

2021/22 was another tough year for community pharmacy as we were still dealing with Covid 19 and the challenges that presented. You all provided amazing support to your patients & communities.

In 2021/22 we saw a number of pharmacies close, along with some mergers and changes of ownership as the larger organisation reviewed their estates.

There are many opportunities coming to improve your service income from more services that the LPC have been working on with commissioners, please ensure you maximise these opportunities.

Summary of the 2022/23 Accounts:

I would like to draw your attention to some key points in the accounts across the following pages.

- 1. We received £14,228 more in grants than 2020/21 this was from the NHSE&I to pay for our Implementation Manger to deliver training and support for CPCS. This balanced the overspend on that expenditure
- 2. The costs for the Committee and Chief office are down by £4,000 which in the mainly is due to Zoom meetings along with incurring less travel expenses
- 3. The extra PSNC levy towards the Wright report this year means that when you add together the two lines for PSNC the spend is the same
- 4. The increase expenditure on PharmOutcomes is offset by the additional income from grants

Jerry

Jerry Long Treasurer



Avon Local Pharmaceutical Committee

Accounts

31 March 2023

DR HICKS

Chartered Accountants 107 Penn Hill Road Bath BA1 3RU

Avon Local Pharmaceutical Committee Accountants' Report

Accountants' report to the directors of Avon Local Pharmaceutical Committee

You consider that the committee is exempt from an audit for the year ended 31 March 2023. You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.

In accordance with your instructions, we have prepared the accounts which comprise the Income and Expenditure Account and the Balance Sheet from the accounting records of the company and on the basis of information and explanations you have given to us.

We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.

DR Hicks

Chartered Accountants

DR Hids

107 Penn Hill Road Bath BA1 3RU

10 July 2023

Avon Local Pharmaceutical Committee Income and Expenditure Account for the year ended 31 March 2023

	2023 £	2022 £
Turnover	328,233	286,273
Staff costs Other charges	(19,783) (297,575)	(17,678) (270,153)
Profit/(Loss) before taxation	10,875	(1,558)
Tax	(26)	-
Profit/(Loss)	10,849	(1,558)

Avon Local Pharmaceutical Committee

Registered number: 99227103

Balance Sheet

as at 31 March 2023

		2023 £		2022 £
Current assets	225,315		291,653	
Creditors: amounts falling due within one year	(6,136)		(203)	
Net current assets	_	219,179	_	291,450
Total assets less current liabilities		219,179		291,450
Accruals and deferred income	_	(107,975)	_	(191,095)
Net assets	<u>-</u>	111,204	_	100,355
General fund		111,204	-	100,355
Average number of employees		Number 1	-	Number 1

The members are satisfied that the committee is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the committee to obtain an audit in accordance with section 476 of the Act

The members acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared in accordance with the micro entity provisions of the Companies Act 2006 and FRS 105, The Financial Reporting Standard applicable to the Micro-entities Regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

L Fisher Chair Person

J Long Treasurer Approved by the board on 10 July 2023

Avon Local Pharmaceutical Committee Detailed income and expenditure account items for the year ended 31 March 2023

This schedule does not form part of the statutory accounts

	2023 £	2022 £
Income	L	L
NHSBSA (Statutory Levy)	210,000	210,000
Sponsorship	3,065	2,080
PharmOutcomes	34,668	32,378
Grants	73,319	39,188
AHS	2,602	2,317
Misc	4,444	310
Bank interest	, 135	-
	328,233	286,273
Staff costs		
Wages and salaries	18,500	17,678
Employer's NI	1,283	-
	19,783	17,678
Other charges		
General administrative expenses:		
Committee admin/Chief Officer	88,373	87,263
Rent and rates	7,140	7,140
Stationery	-	321
Implementation manager	39,516	37,511
PC manager	10,928	11,100
IP Project manager	5,281	-
Training	17,919	3,516
PSNC Levy	69,042	71,000
PharmOutcomes	38,156	27,773
Pharmacy support	17,412	18,458
Telephone and internet charges	449	910
IT software and consumables	-	2,400
Misc	1,927	536
	296,143	267,928
Legal and professional costs:		
Accountancy fees	1,182	1,325
Social media advertising	250	900
	1,432	2,225
	297,575	270,153

Avon Local Pharmaceutical Committee Detailed balance sheet items as at 31 March 2023

This schedule does not form part of the statutory accounts

	2023 £	2022 £
	_	_
Current assets		
Trade debtors	190	136,009
Cash at bank and in hand	225,125	155,644
	225,315	291,653
Creditors: amounts falling due within one year		
Trade creditors	5,453	-
Corporation tax	26	-
Other taxes and social security costs	506	125
Other creditors	151	78_
	6,136	203
Accruals and deferred income		
Deferred income	107,975	191,095
General fund		
Profit and loss account	111,204	100,355
Profit and loss account		
Brought forward	100,355	101,913
Profit/(Loss)	10,849	(1,558)
	111,204	100,355